Moomoo AI 已提取核心信息
Mangoceuticals, Inc. has announced the successful completion of its public offering, including the full exercise of the over-allotment option by underwriters. The event, initially reported in a Form 8-K filed on December 19, 2023, detailed the company's entry into an underwriting agreement with Boustead Securities, LLC on December 15, 2023. The offering involved the sale of 4,000,000 shares of common stock at $0.30 per share. On January 18, 2024, the underwriters exercised their option to purchase an additional 600,000 shares, which closed on January 22, 2024, bringing the total shares sold to 4,600,000. The net proceeds from the additional shares amounted to approximately $160,000. Concurrently, Mangoceuticals issued a common stock purchase warrant to the representative for the purchase of 42,000 shares at $0.375 per share, exercisable until December 14, 2028. The warrant includes anti-dilution provisions and piggyback registration rights. Both the warrant and the underlying shares were registered under the company's Registration Statement.
Mangoceuticals, Inc. has announced the successful completion of its public offering, including the full exercise of the over-allotment option by underwriters. The event, initially reported in a Form 8-K filed on December 19, 2023, detailed the company's entry into an underwriting agreement with Boustead Securities, LLC on December 15, 2023. The offering involved the sale of 4,000,000 shares of common stock at $0.30 per share. On January 18, 2024, the underwriters exercised their option to purchase an additional 600,000 shares, which closed on January 22, 2024, bringing the total shares sold to 4,600,000. The net proceeds from the additional shares amounted to approximately $160,000. Concurrently, Mangoceuticals issued a common stock purchase warrant to the representative for the purchase of 42,000 shares at $0.375 per share, exercisable until December 14, 2028. The warrant includes anti-dilution provisions and piggyback registration rights. Both the warrant and the underlying shares were registered under the company's Registration Statement.
Mangoceuticals, Inc.已宣布成功完成其公开募股，包括承销商全面行使超额配股权。该事件最初在2023年12月19日提交的8-K表格中报告，详细介绍了该公司于2023年12月15日与Boustead Securities, LLC签订承保协议的情况。此次发行涉及以每股0.30美元的价格出售4,000,000股普通股。2024年1月18日，承销商行使了额外购买60万股股票的选择权，该期权于2024年1月22日收盘，使出售的股票总数达到460万股。额外股份的净收益约为160,000美元。同时，Mangoceuticals向该代表签发了普通股购买权证，要求以每股0.375美元的价格购买42,000股股票，行使期至2028年12月14日。认股权证包括反稀释条款和搭便车注册权。认股权证和标的股票均根据公司的注册声明进行注册。
Mangoceuticals, Inc.已宣布成功完成其公开募股，包括承销商全面行使超额配股权。该事件最初在2023年12月19日提交的8-K表格中报告，详细介绍了该公司于2023年12月15日与Boustead Securities, LLC签订承保协议的情况。此次发行涉及以每股0.30美元的价格出售4,000,000股普通股。2024年1月18日，承销商行使了额外购买60万股股票的选择权，该期权于2024年1月22日收盘，使出售的股票总数达到460万股。额外股份的净收益约为160,000美元。同时，Mangoceuticals向该代表签发了普通股购买权证，要求以每股0.375美元的价格购买42,000股股票，行使期至2028年12月14日。认股权证包括反稀释条款和搭便车注册权。认股权证和标的股票均根据公司的注册声明进行注册。
有用
没用